Organization
Icosavax
3 clinical trials
1 abstract
Clinical trial
A Phase 1 Randomized, Observer-blind, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Immunogenicity of IVX-A12, a Respiratory Syncytial Virus and Human Metapneumovirus Bivalent Combination Virus-like Particle Protein Subunit Vaccine, in Healthy Adults, 60 to 75 Years of AgeStatus: Completed, Estimated PCD: 2024-01-24
Clinical trial
A Phase 2a Randomized, Observer-blind, Placebo-controlled, Dosage Optimization, Multi-center Clinical Trial to Evaluate the Safety and Immunogenicity of IVX-A12, a Respiratory Syncytial Virus and Human Metapneumovirus Bivalent Combination Virus-like Particle Protein Subunit Vaccine, in Adults 60 to 85 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2025-07-05
Abstract
Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.Org: Dana-Farber Cancer Institute, St. Luke’s Hospital, Division of Urology, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Tor Vergata University of Rome,
Clinical trial
A Phase 2, Randomized, Modified Double-Blind, Active Controlled Study to Characterize the Safety and Immunogenicity of IVX-A12 in Adults 60 Years of Age and OlderStatus: Active (not recruiting), Estimated PCD: 2024-07-19